论文部分内容阅读
目的：探讨核仁组成区嗜银蛋白（ＡｇＮＯＲ）和肾肿瘤的分类、临床分期的关系。方法：用胶体银技术对１１６例肾肿瘤和１１例正常肾组织进行ＡｇＮＯＲ计数并进行分析。结果：ＡｇＮＯＲ计数在肾盂癌、肾细胞癌和Ｗｉｌｍ氏瘤中分别为５．２３±１．４、４．１２±１．２和３．９８±０．９；肾错钩瘤和正常肾组织分别为１．８６±０．９和１．６３±０．７；ＡｇＮＯＲ计数在肾脏良恶性肿瘤之间差异非常显著（Ｐ＜０．０１），肾细胞癌临床Ⅰ、Ⅱ、Ⅲ和Ⅳ期ＡｇＮＯＲ数目分别为３．６５±０．３、４．０２±０．５、４．６２±０．３和４．５８±０．４。结论：ＡｇＮＯＲ计数随肾细胞癌的临床分期升高而增加，可作为鉴别肾脏良恶性肿瘤的重要参考指标
Objective: To investigate the relationship between the classification and clinical stage of AgNOR in renal cell carcinoma. METHODS: AgNOR counts of 116 renal tumors and 11 normal renal tissues were performed using colloidal silver technique and analyzed. Results: AgNOR counts were 5.23 ± 1.4, 4.12 ± 1.2 and 3.98 ± 0.9 in renal pelvis, renal cell carcinoma and Wilm’s tumor respectively. Respectively, 1.86 ± 0.9 and 1.63 ± 0.7, respectively. The difference of AgNOR counts between benign and malignant neoplasms was significant (P <0.01). The clinical stage Ⅰ, Ⅱ, Ⅲ and Ⅳ of renal cell carcinoma The numbers of AgNORs were 3.65 ± 0.3, 4.02 ± 0.5, 4.62 ± 0.3 and 4.58 ± 0.4, respectively. Conclusion: AgNOR counts increase with the clinical stage of renal cell carcinoma, which can be used as an important reference to identify benign and malignant renal neoplasms